Search

Cheng C Zhu

from Raritan, NJ
Age ~63
Get Report
Also known as:
Cheng Huinan Zhu, Chuck Cheng Zhu, Chuck C Zhu, Cheng Z Hu, Charles Zhu, Chad C Weber, Chen Zhou
Phone and address:
1 Bluebird Way, Raritan, NJ 08869
(908) 253-9453
Related to:
Rong P ZhouXiaosui Hu, 69Kevin Chu, 46Jill Beyonce
Connected to:
Abby Zhu, 40Ada Zhu, 32Aileen J Zhu, 31Alyssa H Zhu, 35Ankang Zhu, 65Anwei W Zhu, 50Audrey Zhu, 27Bai C Zhu, 70Bangmin Zhu, 58Bao Y Zhu, 51

Cheng Zhu Phones & Addresses

  • 1 Bluebird Way, Raritan, NJ 08869 (908) 253-9453
  • North Port, FL
  • Hillsborough, NJ
  • 3100 Parkway Blvd #222, Kissimmee, FL 34747 (908) 253-9453
  • 2076 Wendys Dr #36, Columbus, OH 43220 (614) 459-9476
  • Bridgewater, NJ
  • Lewis Center, OH
  • Dallas, TX
  • Garland, TX

Publications

Us Patents

Substituted Imidazole-4-Carboxamides As Cholecystokinin-1 Receptor Modulators

View page
US Patent:
7759352, Jul 20, 2010
Filed:
Apr 10, 2007
Appl. No.:
12/226115
Inventors:
Joseph L. Duffy - Cranford NJ, US
Scott Edmondson - Clark NJ, US
Hansen Alexa - Danville CA, US
Cheng Zhu - Scotch Plains NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/4178
A61K 31/454
A61K 31/496
C07D 233/94
C07D 403/04
C07D 405/04
US Classification:
51425405, 51425407, 514319, 544370, 546205
Abstract:
Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

Substituted Imidazole 4-Carboxamides As Cholecystokinin-1 Receptor Modulators

View page
US Patent:
7795265, Sep 14, 2010
Filed:
Apr 10, 2007
Appl. No.:
12/225906
Inventors:
Richard Berger - Princeton NJ, US
Scott Edmondson - Clark NJ, US
Alexa Hansen - Danville CA, US
Cheng Zhu - Edison NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/4178
A61K 31/454
A61K 316/496
C07D 233/94
C07D 403/04
C07D 405/04
US Classification:
51425405, 51425407, 514319, 544121, 544364, 544370, 544187, 546205, 546187
Abstract:
Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

Substituted Imidazole 4-Carboxamides As Cholecystokinin-1 Receptor Modulators

View page
US Patent:
7858629, Dec 28, 2010
Filed:
Apr 10, 2007
Appl. No.:
12/226048
Inventors:
Richard Berger - Princeton NJ, US
Scott Edmondson - Clark NJ, US
Alexa Hansen - Danville CA, US
Cheng Zhu - Edison NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/496
A61K 31/4709
A61K 31/454
C07D 405/14
C07D 413/14
US Classification:
51425306, 51425405, 51425407, 514314, 514326, 544121, 544129, 544363, 544370, 546175, 546205
Abstract:
Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

Substituted Imidazole 4-Carboxamides As Cholecystokinin-1 Receptor Modulators

View page
US Patent:
7977339, Jul 12, 2011
Filed:
Aug 3, 2010
Appl. No.:
12/849061
Inventors:
Richard Berger - Princeton NJ, US
Scott Edmondson - Clark NJ, US
Alexa Hansen - Danville CA, US
Cheng Zhu - Edison NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/496
A61K 31/454
A61K 31/4178
US Classification:
51425405, 51425407, 514319, 544370, 546205
Abstract:
Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

Hydroxymethyl Pyrrolidines As Β3 Adrenergic Receptor Agonists

View page
US Patent:
8247415, Aug 21, 2012
Filed:
Apr 2, 2009
Appl. No.:
12/417239
Inventors:
Richard Berger - Princeton NJ, US
Lehua Chang - Ramsey NJ, US
Scott D. Edmondson - Clark NJ, US
Stephen D. Goble - Edison NJ, US
Sookhee Nicole Ha - Warren NJ, US
Nam Fung Kar - Brooklyn NY, US
Ihor E. Kopka - Hampton NJ, US
Bing Li - Towaco NJ, US
Gregori J. Morriello - Randolph NJ, US
Chris R. Moyes - Westfield NJ, US
Liping Wang - Dayton NJ, US
Cheng Zhu - Edison NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 237/30
C07D 239/90
C07D 221/02
C07D 277/60
A61K 31/502
A61K 31/517
A61K 31/435
A61K 31/428
A61P 13/10
A61P 13/06
US Classification:
514248, 5142593, 5142662, 514306, 544237, 544282, 544253, 546138, 548159
Abstract:
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

Pyrrolidine Derived Beta 3 Adrenergic Receptor Agonists

View page
US Patent:
8354403, Jan 15, 2013
Filed:
Aug 17, 2010
Appl. No.:
13/392662
Inventors:
Scott D. Edmondson - Clark NJ, US
Richard Berger - Princeton NJ, US
Lehua Chang - Ramsey NJ, US
Vincent J. Colandrea - North Brunswick NJ, US
Jeffrey J. Hale - Westfield NJ, US
Bart Harper - New York NY, US
Nam Fung Kar - Brooklyn NY, US
Bing Li - Towaco NJ, US
Greg J. Morriello - Randolph NJ, US
Christopher R. Moyes - Westfield NJ, US
Deyou Sha - Yardley PA, US
Liping Wang - Cranbury NJ, US
Harvey Wendt - Medford Lakes NJ, US
Cheng Zhu - Edison NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/536
A61K 31/438
A61K 31/4245
C07D 265/12
C07D 221/20
C07D 413/14
US Classification:
5142305, 514278, 514364, 544 92, 546 16, 548131
Abstract:
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists

View page
US Patent:
8399480, Mar 19, 2013
Filed:
Apr 2, 2009
Appl. No.:
12/936221
Inventors:
Richard Berger - Princeton NJ, US
Lehua Chang - Ramsey NJ, US
Scott D. Edmondson - Clark NJ, US
Stephen D. Goble - Edison NJ, US
Sookhee Nicole Ha - Warren NJ, US
Nam Fung Kar - Brooklyn NY, US
Ihor E. Kopka - Hampton NJ, US
Bing Li - Towaco NJ, US
Gregori J. Morriello - Randolph NJ, US
Chris R. Moyes - Westfield NJ, US
Liping Wang - Dayton NJ, US
Cheng Zhu - Edison NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 43/90
A01K 31/44
C07D 237/00
US Classification:
514306, 514248, 514249, 5142662, 544237, 544253, 544282, 546138, 548159
Abstract:
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists

View page
US Patent:
8501786, Aug 6, 2013
Filed:
Mar 23, 2009
Appl. No.:
12/936275
Inventors:
Richard Berger - Princeton NJ, US
Lehua Chang - Ramsey NJ, US
Scott D. Edmondson - Clark NJ, US
Stephen D. Goble - Edison NJ, US
Bart Harper - New York NY, US
Nam Fung Kar - Brooklyn NY, US
Ihor E. Kopka - Hampton NJ, US
Bing Li - Towaco NJ, US
Gregori J. Morriello - Randolph NJ, US
Chris R. Moyes - Westfield NJ, US
Liping Wang - Dayton NJ, US
Harvey Wendt - Medford Lakes NJ, US
Cheng Zhu - Edison NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/443
A61K 31/4436
A61K 31/4439
C07D 401/14
C07D 413/14
C07D 417/14
US Classification:
514340, 514336, 514341, 514342, 5462691, 5462714, 5462724, 5462684, 5462727, 5462754, 5462764
Abstract:
The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
Control profile
Cheng C Zhu from Raritan, NJ, age ~63 Get Report